Best Neurology Companies in Cambridge, United States

Developer of small molecule-based therapeutics for the treatment of obstructive sleep apnea. The company has developed a combination of Atomoxetine and Oxybutynin which reduces the obstructive sleep apnea severity. It targets the neurological control and activation of upper airway dilator muscles which improve respiration and oxygenation during sleep.

Funding rounds

• Apr 2026Conventional Debt$50M
• Mar 2026Series C$25M
• Sep 2025Conventional Debt$35M
• Apr 2025Series C$16.5M

Founders & team

Andrew WellmanCo-FounderLawrence MillerCo-Founder

Investors

Tao Capital Partners, Morningside, Alpha Wave Global, Sectoral, Columbia-Seligman Investments, NexPoint

Tech stack

Apple Icloud MailCloudflareCloudflare Bot ManagementCookieyesCore-JsDocusign

Developer of a medical device for the treatment of Alzheimer's disease. The device uses gamma stimulation which helps in reactivating the immune system of the brain. It results in the reduction of amyloid plaques and tau tangles which are typical hallmarks of the disease.

Funding rounds

• Mar 2026Series C$105M
• Mar 2025Series C$196.3M
• Jun 2024Series B$10.2M
• Jun 2022Series B$108.8M

Founders & team

Ed BoydenCo-FounderLi-Huei TsaiCo-FounderChristian HowellChief Executive Officer

Investors

Morningside, FoundersX Ventures, Alzheimer's Drug Discovery, LIfT Biosciences, IAG Capital Partners, WS Investment Company

Tech stack

CdnjsCloudflareCraft CmsFacebook PixelGoogle AnalyticsGoogle Tag Manager

Developer of gene therapy platform for Duchenne muscular dystrophy. The lead candidate SGT-001 is Microdystrophin, a synthetic version of the dystrophin gene which stabilizes the muscle membrane and dystrophin-glycoprotein complex. Also, developed a soft wearable device for mobility and help preserve muscle function.

Developer of transformational medicines for neurological disorders. The company combines advanced human cellular models, unique measurement engineering, artificial intelligence, and machine learning into a proprietary platform to discover new drugs for neurological disease. The company's lead candidate is UBE3A for Seizure and Neurodevelopment Disorders.

Funding rounds

• Apr 2026Series B—
• Dec 2025Grant (prize money)$3M
• Jul 2025Grant (prize money)$2.1M
• Mar 2025Grant (prize money)$2.2M

Founders & team

Paul RomaCo-FounderGraham DempseyCo-FounderDavid MarguliesCo-Founder and Chairman

Investors

NIH, HHS

Developer of small molecule therapeutics targeting neurodegenerative diseases of the CNS. It utilizes a platform to identify cell-to-cell interactions. The lead program is a small molecule inhibitor of EphB3. EphB3 is a receptor tyrosine kinase mediating microglia-astrocyte interactions. These interactions drive glial dysfunction.

Funding rounds

• May 2026Seed$4.8M
• May 2023Seed$10.6M

Founders & team

Meredith FisherCo-Founding & CEOFrancisco QuintanaCo-Founder

Investors

SV Health Investors, UTEC, Partners HealthCare, Ono Venture Investment, LifeSpan Vision Ventures, Mass General Brigham

QurAlis is engaged in discovering and developing new therapies for amyotrophic lateral sclerosis (ALS), which is a common form of motor neuron disease. The company has developed Optopatch technology which helps in stimulating the neurons and notes their electrical behavior. Their proprietary method clears toxic proteins and transcranial magnetic stimulation helps in diagnosing ALS by identifying biomarkers such as protein in the blood. In addition, other therapeutic targets like nerve threshold tracking, proteins in the cerebral spinal fluid helps to predict ALS. The company has a preclinical-stage program for ALS drugs targeting the Kv7.2/7.3 channel & CSF cartridge device to remove DPR proteins.

Funding rounds

• Aug 2025Series B$20M
• Mar 2023Series B$88M
• Sep 2022Grant (prize money)$300K
• Jul 2020Grant (prize money)$107.4K

Founders & team

Kasper RoetFounder & CEO

Investors

Polaris Partners, Mission BioCapital, MP Healthcare Venture Management, Dolby Family Ventures, SV Health Investors, Droia Ventures

Tech stack

AccessibeApple Icloud MailCloudflareCloudflare Bot ManagementCookieyesGenesis Blocks

Developer of small molecule therapeutics for neurodegenerative disease. The company offers autophagosome-tethering compounds that enhances the degradation of disease-causing protein and non-protein targets.

Funding rounds

• Jan 2026Series B$38M
• May 2025Series B$39M
• Jul 2021Series A$30M
• 2020Seed$4M

Founders & team

Huaixiang HaoCo-FounderBoxun LuCo-FounderNan JiCo-Founder

Investors

Nest Bio Ventures, Matrix Partners China, Sherpa Healthcare Partners, Huagai Capital, MSA Capital, MRLV

Developer of RNA-based therapeutics for multiple disorders. It is building compound libraries likely to recognize the RNA target sites and modulate their function, particularly those mediated by the regulatory proteins. The data-driven mRNA target identification platform accounts for cell type-specific target regulation and predicts the biological consequences of target modulation.

Funding rounds

• 2025Series A—
• Nov 2022Series A$52M
• May 2021Seed$18M
• Sep 2020Grant (prize money)$400K

Founders & team

Zhiping WengCo-FounderSimon XiCo-Founder and CEOTravis WagerCo-Founder

Investors

Boehringer Ingelheim Venture Fund, Matrix Partners China, AstraZeneca, Delos Capital, Matrix, Lilly Asia Ventures

Developer of bioelectronic fibers for neuromodulation and neural interface applications. The company focuses on creating minimally invasive technologies that interact with the body's biological environment. Their fibers are designed to sense and modulate electrical, chemical, and mechanical signals. The technology aims to expand access to therapies like deep brain stimulation through less invasive delivery methods. The company also provides tools for neuroscience research, supporting electrical, optical, and chemical recording and stimulation.

Funding rounds

• Nov 2025Seed$10M
• Aug 2024Grant (prize money)$254.5K

Founders & team

Marc-Joseph AntoniniCo-Founder & CEO

Investors

National Science Foundation, Future Ventures, Vanedge Capital, Lionheart Ventures, Gaingels, Dolby Family Ventures

Tech stack

ComplianzContact Form 7DiviGoogle AnalyticsGoogle Font ApiGoogle Tag Manager

Developer of autologous cell therapies. The company has developed an AI-guided laser editing platform, single-cell laser processing, and robotics to generate autologous induced pluripotent stem cells for regenerative medicines for diseases like Parkinson’s, diabetes, and heart disease.

Funding rounds

• Sep 2024Series A$25M
• Jan 2022Series A$80M
• Feb 2021Seed$16M
• Aug 2019Seed$2.5M

Founders & team

Matthias WagnerCo-Founder & CTOMarinna MadridCo-FounderNabiha SaklayenCo-Founder & CEO

Investors

Khosla Ventures, Humboldt Fund, 8VC, Engine Ventures, MassChallenge, Leaps by Bayer

Tech stack

GodaddyGoogle AnalyticsGoogle WorkspaceGsapHstsLenis

Precision dosing for CNS diseases through innovative neurotechnology platform. This is a neurotechnology business focused on improving and extending the lives of patients with central nervous system disorders. They utilize a proprietary platform to deliver therapeutics with precision, aiming for efficacious levels while minimizing side effects. Their strategy involves launching into neuro-oncology and leveraging partnerships to expand into neurodegenerative, lysosomal storage, and autoimmune diseases. The platform offers controlled, continuous, and personalized delivery of both existing and next-generation therapeutics to targeted areas of the CNS. They are building an integrated business with a pipeline of patient-focused opportunities, utilizing machine learning and artificial intelligence for closed-loop control. This approach allows for precision dosing of CNS-based therapeutics, addressing a significant market need and offering potential for personalized medicine.

Developer of therapeutic solutions for treating multiple neurodegenerative diseases. The company is developing microglia-focused therapeutic solutions to treat rare and common neurodegenerative diseases. The lead candidate VGL101 is a monoclonal antibody agonist of TREM2, a transmembrane receptor expressed selectively on microglia.

Funding rounds

• Jul 2024Post IPO$40M
• Aug 2021Series B$90M
• Dec 2020Series A$50M

Founders & team

Ivana LiebischCEO & President

Investors

Vida Ventures, Hatteras Venture Partners, Citadel, Orbimed, Deep Track Capital, Invus